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Background Implantable cardioverter defibrillators (ICD) are recommended
in patients with low ejection fraction. However the survival benefit of ICD in
patients with end-stage heart failure listed for heart transplantation is unclear. 
Aim The objective was to evaluate the ICD benefit on mortality in this
population. 
Methods 380 consecutive patients listed for heart transplantation between
2005 and 2009 in one tertiary heart transplant center were enrolled in a retro-
spective registry. 122 patients received an ICD before or within 3 months after
registry (ICD-group). Predictors of death in the waiting list were assessed by
Cox regression.
Results 15.6% of patients died while awaiting heart transplantation. Non-
ICD patients presented more often haemodynamic compromise requiring
mechanical circulatory support (MCS, 34.2% vs 14.9%, p<0.0001) and were
more likely to die while in the waiting list (19.0% vs 8.3%, p=0.006). How-
ever, in the multivariate model, ICD did not remain an independent predictor
of death. The need for a MCS and LVEF were the only independent predictors
of death (p<0.0001 and p=0.001). 
Death was mainly due to haemodynamic compromise (76.6% of deaths),
which occurred more frequently in the non-ICD group (14.7% vs 5.8%,
p=0.019). Unknown/arrhythmic deaths did not significantly differ between the
two groups (3.9% vs 1.7%, p=0.19). ICD-related complications occurred in
21.4% of patients, mainly due post-operative worsening of heart failure (11.9%).
Conclusion Haemodynamic failure appears as the main determinant of
mortality in patients awaiting heart transplantation. ICD seems to have little
benefit on survival in this population. 
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Implantable cardioverter defibrillator (ICD) has been shown to be associ-
ated with a significant reduction in the risk of sudden cardiac death. The aim
of this study was to assess the prevalence and to identify the clinical predictors
of appropriate ICD therapy in patients with chronic heart failure following
implantation of an ICD for primary prevention. A monocenter retrospective
analysis was performed and all consecutive patients undergoing implantation
of ICD for primary prevention were included. Device interrogations were per-
formed and appropriate therapies were recorded. The endpoint follow-up was
the last available device interrogation in our center. Of 317 primary prevention
patients undergoing ICD implantation, 203 (64%) had ischemic cardiomyo-
pathy (ICM) and 114 had non-ischemic dilated cardiomyopathy (NIDCM).
After a mean follow-up time 760±599 days, 56 (17.7%) had received appro-
priate ICD therapies. Mean LVEF was 26±6%. By univariate comparison,
LVDD≥65mm (p=0.035) and lack of diuretic (p=0.024) were predictors for
ICD therapy. Absence of cardiac resynchronization therapy device (CRTD)
was close to be significant (p=0.055). ICM and NIDCM patients benefit from
ICD implantation did not differ (p=0.941). By multivariate analysis, elderly
patients ≥65y (HR 1.92, p=0.032), LVDD≥65mm (HR 2.01, p=0.022) and
lack of diuretic (HR 0.31, p<0.001) were all significant independent predictors
for ICD therapy. Overall, the absence of CRTD device was close to be signi-
ficant (H 0.53, p=0.062), but was significant in NIDCM population (p=0.007).
During follow-up, the onset of atrial fibrillation (p=0.027) and hospitalization
for acute heart failure (p=0.002) were significantly associated with ICD-
delivered therapy. ICD therapy occurred in 17.7% of primary prevention
patients without any difference between ICM and NIDCM. Older age, LV
dilatation and absence of diuretic were predictive factors for ICD therapy.
Presence of CRTD was close to be significant (figure next page).
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Abstract 0376 – Figure: Survival free of late AF and AFL by transplant
